Alex Burgin

Title: Alex Burgin: Innovator in Pharmaceutical Compounds

Introduction

Alex Burgin is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating hyperproliferative diseases and cancer. With a total of 6 patents, his work has had a substantial impact on medical research and treatment methodologies.

Latest Patents

Among his latest patents, one focuses on dihydrooxadiazinone compounds. This invention provides compounds of general formula (I), where R, R, R, and R are defined within the patent. It includes methods for preparing these compounds, intermediate compounds useful for their preparation, and pharmaceutical compositions for treating diseases, especially hyperproliferative diseases. Another significant patent features improved compounds and methods for identifying cancer patients using biomarkers such as PDE3A, SLFN12, and CREB3L1. This innovation aims to correlate drug sensitivity with patient stratification, allowing for more effective treatment options.

Career Highlights

Alex Burgin has worked with prominent organizations in the pharmaceutical industry. Notably, he has been associated with Bayer Pharma and The Broad Institute, where he has contributed to groundbreaking research and development in drug formulation and patient treatment strategies.

Collaborations

Throughout his career, Alex has collaborated with esteemed colleagues, including Heidi Greulich and Xiaoyun Wu. These partnerships have fostered innovation and enhanced the quality of research in their respective fields.

Conclusion

In summary, Alex Burgin is a distinguished inventor whose work in pharmaceutical compounds has paved the way for advancements in cancer treatment and patient care. His contributions continue to influence the medical field significantly.